Entering text into the input field will update the search result below

Biogen ends partnership with Catalyst Biosciences for eye disease candidate

Mar. 16, 2022 11:52 AM ETBiogen Inc. (BIIB) Stock, CBIO StockBy: Dulan Lokuwithana, SA News Editor2 Comments

Termination of contract agreement. Word Terminated printed on a document.

Olivier Le Moal/iStock via Getty Images

  • Biogen (NASDAQ:BIIB) and Catalyst Biosciences (NASDAQ:CBIO) have ended their collaboration on potential treatments for dry AMD (dAMD), a leading cause of blindness.
  • Per the terms of the agreement, the Alzheimer’s drug developer has returned

Recommended For You

Related Stocks

SymbolLast Price% Chg
BIIB
--
CBIO
--